These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


446 related items for PubMed ID: 7521907

  • 1. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.
    Stahel RA, Jost LM, Cerny T, Pichert G, Honegger H, Tobler A, Jacky E, Fey M, Platzer E.
    J Clin Oncol; 1994 Sep; 12(9):1931-8. PubMed ID: 7521907
    [Abstract] [Full Text] [Related]

  • 2. Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas.
    Stahel RA, Jost LM, Honegger H, Betts E, Goebel ME, Nagler A.
    J Clin Oncol; 1997 May; 15(5):1730-5. PubMed ID: 9164179
    [Abstract] [Full Text] [Related]

  • 3. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Smith TJ, Hillner BE, Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Link H, Zander A, Yanovich S, Kitchin R, Erder MH.
    J Clin Oncol; 1997 Jan; 15(1):5-10. PubMed ID: 8996118
    [Abstract] [Full Text] [Related]

  • 4. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients.
    Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Demuynck HM, Link H, Zander A, Barge A.
    Lancet; 1996 Feb 10; 347(8998):353-7. PubMed ID: 8598700
    [Abstract] [Full Text] [Related]

  • 5. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma.
    Lemoli RM, Rosti G, Visani G, Gherlinzoni F, Miggiano MC, Fortuna A, Zinzani P, Tura S.
    J Clin Oncol; 1996 Nov 10; 14(11):3018-25. PubMed ID: 8918500
    [Abstract] [Full Text] [Related]

  • 6. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation.
    Schmitz N, Dreger P, Zander AR, Ehninger G, Wandt H, Fauser AA, Kolb HJ, Zumsprekel A, Martin A, Hecht T.
    Bone Marrow Transplant; 1995 Feb 10; 15(2):261-6. PubMed ID: 7539668
    [Abstract] [Full Text] [Related]

  • 7. Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease.
    Taylor KM, Jagannath S, Spitzer G, Spinolo JA, Tucker SL, Fogel B, Cabanillas FF, Hagemeister FB, Souza LM.
    J Clin Oncol; 1989 Dec 10; 7(12):1791-9. PubMed ID: 2479719
    [Abstract] [Full Text] [Related]

  • 8. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
    Nademanee A, Sniecinski I, Schmidt GM, Dagis AC, O'Donnell MR, Snyder DS, Parker PM, Stein AS, Smith EP, Molina A.
    J Clin Oncol; 1994 Oct 10; 12(10):2176-86. PubMed ID: 7523609
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy.
    Weaver CH, Appelbaum FR, Petersen FB, Clift R, Singer J, Press O, Bensinger W, Bianco J, Martin P, Anasetti C.
    J Clin Oncol; 1993 Jul 10; 11(7):1329-35. PubMed ID: 8315430
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients--results of a phase I/II trial.
    Moskowitz CH, Stiff P, Gordon MS, McNiece I, Ho AD, Costa JJ, Broun ER, Bayer RA, Wyres M, Hill J, Jelaca-Maxwell K, Nichols CR, Brown SL, Nimer SD, Gabrilove J.
    Blood; 1997 May 01; 89(9):3136-47. PubMed ID: 9129016
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor Therapy.
    Fridrik MA, Greil R, Hausmaninger H, Krieger O, Oppitz P, Stöger M, Klocker J, Neubauer M, Helm W, Pont J, Fazeny B, Hudec M, Simonitsch I, Radaszkiewicz T.
    Ann Hematol; 1997 Oct 01; 75(4):135-40. PubMed ID: 9402845
    [Abstract] [Full Text] [Related]

  • 16. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
    Perrier L, Lefranc A, Pérol D, Quittet P, Schmidt-Tanguy A, Siani C, de Peretti C, Favier B, Biron P, Moreau P, Bay JO, Lissandre S, Jardin F, Espinouse D, Sebban C.
    Appl Health Econ Health Policy; 2013 Apr 01; 11(2):129-38. PubMed ID: 23435861
    [Abstract] [Full Text] [Related]

  • 17. Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC). Medical Research Council Lung Cancer Working Party.
    Thatcher N, Clark PI, Smith DB, Anderson H, Girling DJ, Machin D, Stephens RJ, Lallemand G, Jenkins B.
    Clin Oncol (R Coll Radiol); 1995 Apr 01; 7(5):293-9. PubMed ID: 8580054
    [Abstract] [Full Text] [Related]

  • 18. Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma.
    Cortelazzo S, Viero P, Bellavita P, Rossi A, Buelli M, Borleri GM, Marziali S, Bassan R, Comotti B, Rambaldi A.
    J Clin Oncol; 1995 Apr 01; 13(4):935-41. PubMed ID: 7535843
    [Abstract] [Full Text] [Related]

  • 19. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
    Todisco E, Castagna L, Sarina B, Mazza R, Magagnoli M, Balzarotti M, Nozza A, Siracusano L, Timofeeva I, Anastasia A, Demarco M, Santoro A.
    Eur J Haematol; 2007 Feb 01; 78(2):111-6. PubMed ID: 17313558
    [Abstract] [Full Text] [Related]

  • 20. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma.
    Sparano JA, Wiernik PH, Hu X, Sarta C, Schwartz EL, Soeiro R, Henry DH, Mason B, Ratech H, Dutcher JP.
    J Clin Oncol; 1996 Nov 01; 14(11):3026-35. PubMed ID: 8918501
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 23.